European OTC Results Round-Up: HRA Pharma, Boiron and Ipsen
Executive Summary
HRA Pharma reports impressive sales growth in 2018, thanks largely to acquisitions. A drop in demand for homeopathic medicines hurts Boiron in Q1, while Ipsen enjoys a solid start to the year.
You may also be interested in...
HRA Pharma Sharpens Focus On OTC With Rare Diseases Split
By shifting its rare diseases portfolio into a newly-created affiliate, HRA Pharma is signalling its intention to become a force in the global consumer healthcare market.
HRA Pharma Breaks Into US Consumer Health Market With Mederma Acquisition
EllaOne and Compeed manufacturer HRA Pharma is set to establish a notable presence in the US consumer health market by acquiring the Mederma dermatology range from Germany's Merz.
France Should Allow Supermarket Sale Of OTCs And Relax Pharmacy Ownership Rules, Says Competition Authority
The French competition authority recommends OTC sales should be permitted outside pharmacy, while more should be done to promote online sales. Furthermore, pharmacy ownership restrictions should be relaxed, the authority says in its wide ranging enquiry into competition in the country's medicines sector.